Central Nervous System Effects of Liraglutide® 3.0 mg on Reward Mechanisms in Obese Patients Without Diabetes, in Relation to Food Addiction. A Randomized, Single-centre, Double-blind, Placebo Controlled Clinical Trial.
Phase of Trial: Phase IV
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms LIRAOB
- 31 Aug 2018 Biomarkers information updated
- 04 Mar 2018 Status changed from not yet recruiting to recruiting.
- 22 Nov 2017 New trial record